Merck KGaA Company

Merck KGaA is currently assessing an interferon beta approved by the FDA for the treatment of relapsing forms of multiple sclerosis; Rebif® (interferon beta-1a).

Merck KGaA said March 19 it donated Rebif to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial. The trial (DisCoVeRy; 2020-000936-23 and NCT04315948) —sponsored by INSERM and launched March 11 — is comparing Rebif to AbbVie’s Kaletra, Gilead Sciences ’Remdesivir, and Sanofi’s Plaquenil (hydroxychloroquine) in 3,100 patients.

Industry: Treatments
Investor Type: N/A
Headquarters: Germany
Investment Stage: N/A
Funding Status: N/A
Employee Number: N/A
Number Of Exists: N/A
Technology: COVID
Founded Date: N/A